NCT05815862已完成2 期
A Multi-cohort, Randomized, Open, Multicenter Phase II Study to Evaluate the Efficacy and Safety of AL2846 Capsules in Treated Subjects With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 29
- 试验地点
- 4
- 主要终点
- Objective remission rate (ORR)
研究概览
简要总结
This is a multi-cohort, randomized, open, multicenter Phase II study to evaluate the efficacy and safety of AL2846 capsules in patients with advanced lung cancer and ovarian cancer. Objective response rate (ORR) and progression-free survival (PFS) are the primary endpoints.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with advanced lung cancer or ovarian cancer confirmed by histopathology or cytology;
- •Age: 18~75 years old (when signing the informed consent form); Eastern Cooperative Oncology Group (ECOG) score: 0-1;
- •At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1;
- •Normal function of main organs
- •The serum Human Chorionic Gonadotropin (HCG) test of female patients of childbearing age must be negative within 7 days before study enrollment and must be non-lactating; The patient should agree to use contraception during the study period and within 6 months after the end of the study period;Male subjects should agree to use contraception during the study period and for 6 months after the study period ends;
- •The patient voluntarily joined the study and signed the informed consent form, with good compliance.
排除标准
- •Combined with the following diseases or medical history:
- •Other malignant tumors have occurred or are present at the same time within<3 years before the first administration.
- •Inability to tolerate multiple factors affecting oral medication due to any reason;
- •Common Terminology Criteria for Adverse Events (CTCAE) 5.0 > grade 1 therapeutic toxicity caused by any previous treatment that has not been completely relieved, excluding hair loss;
- •Major surgical treatment or obvious traumatic injury was received within 4 weeks before the first administration;
- •The presence of unhealed wounds, fractures, gastric and duodenal active ulcers, persistent positive fecal occult-blood, ulcerative colitis, or other conditions determined by investigators that may cause gastrointestinal bleeding or perforation;
- •Arteriovenous thrombosis, such as cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc., occurred within 6 months before the first medication;
- •Those who have a history of psychotropic drug abuse and cannot abstain or have mental disorders;
- •Subjects with any severe and/or uncontrollable disease；
- •Tumor related symptoms and treatment:
- •Had received chemotherapy, radiation, or other anticancer therapy within 4 weeks prior to first dose;
- •Within 2 weeks before the first dose, received Chinese Traditional drugs with anti-tumor indications specified in theNational Medical Products Administration (NMPA) approved drug instructions
- •Previously treated with anti-angiogenic drugs such as Cabozantinib, Anlotinib, Endostar and Bevacizumab;
- •Imaging Computed Tomography (CT)or Magnetic Resonance Imaging (MRI) shows that the tumor has invaded important blood vessels or the investigator determines that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during the follow-up study;
- •There is a history of interstitial lung disease, severe impairment of lung function, severe pulmonary fibrosis, severe radiation pneumonia, drug-induced lung disease, and evidence of severe active lung inflammation indicated by chest CT examination during screening;
- •There are uncontrolled pleural effusion, ascites and moderate or above pericardial effusion requiring repeated drainage;
- •Patients with brain metastases accompanied by symptoms or symptoms controlled for less than 2 weeks;
- •Patients who have participated in and used other antitumor investigational drugs within 4 weeks before the first dose;
- •Central squamous cell carcinoma (lung cancer subjects) with great risk of hemoptysis;
- •Patients with concomitant diseases that, in the opinion of the investigators, seriously endanger the safety of the patients or affect the completion of the study, or who are not suitable for inclusion for other reasons.
研究组 & 干预措施
AL2846 capsule
Experimental
orally administer AL2846 capsules monotherapy, 28 days as a treatment cycle.
干预措施: AL2846 capsule (Drug)
结局指标
主要结局
Objective remission rate (ORR)
时间窗: From baseline up to 12 months.
ORR is defined as the percentage of subjects in complete remission (CR), partial remission (PR), and disease stability (SD).
Progression free survival (PFS)
时间窗: From baseline up to 12 months.
PFS is defined as the time from randomization to the first recorded progressive disease (PD) or death from any cause.
次要结局
- Overall survival (OS)(From baseline to the death events, assessed up to 3 years.)
- Adverse events (AEs) rate(From baseline to 28 days after the last dose or initiation of a new antineoplastic therapy (whichever comes first).)
- Area under blood concentration-time curve (AUC)(Pre-dose, 30 minutes, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours and 24 hours after dose on Day 1 and Day 28 of Cycle 1. Pre-dose on Day 7, Day 14 and 21 of cycle 1. Each cycle is 28 days.)
- Disease control rate (DCR)(From baseline up to 12 months.)
- Peak concentration (Cmax)(Pre-dose, 30 minutes, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours and 24 hours after dose on Day 1 and Day 28 of Cycle 1. Pre-dose on Day 7, Day 14 and 21 of cycle 1. Each cycle is 28 days.)
- Time to peak concentration (Tmax)(Pre-dose, 30 minutes, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours and 24 hours after dose on Day 1 and Day 28 of Cycle 1. Pre-dose on Day 7, Day 14 and 21 of cycle 1. Each cycle is 28 days.)
- Duration of remission (DOR)(From baseline up to 12 months.)
- Clearance half life (t1/2)(Pre-dose, 30 minutes, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours and 24 hours after dose on Day 1 and Day 28 of Cycle 1. Pre-dose on Day 7, Day 14 and 21 of cycle 1. Each cycle is 28 days.)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple MyelomaMultiple MyelomaNCT03601078Celgene312
Unknown
2 期
Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical ResectionHepatocellular Carcinoma (HCC)NCT05213637Chinese PLA General Hospital430
招募中
2 期
A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis BChronic Hepatitis BNCT06425341Fujian Shengdi Pharmaceutical Co., Ltd.369
Unknown
2 期
Phase II Study in the Treatment of Patients With Advanced Mucinous MelanomaAdvanced Mucosal MelanomaNCT03941795Peking University Cancer Hospital & Institute99
进行中（未招募）
2 期
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing TumorsPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerNCT04482309AstraZeneca477